The FDA has accepted for review a supplemental application for taletrectinib in advanced ROS1-positive NSCLC, with a PDUFA date of January 4, 2027. Updated TRUST-I and TRUST-2 data showed high response rates, durable responses and no new safety signals.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
Zocilurtatug pelitecan showed an overall response rate of 38.2% and a disease control rate of 55.9% in 34 patients with pretreated extrapulmonary neuroendocrine carcinomas. Grade 3 or higher treatment-emergent adverse effects occurred in 30.4% of patients.
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Norovirus has been making its rounds again during the winter season, causing vomiting, diarrhea and stomach cramps that usually clear within one to three days. There is no specific medication, and hydration, bland foods and strict handwashing are the main measures recommended.
The FDA has announced plans to crack down on active pharmaceutical ingredients used in compounded GLP-1 drugs and warned about the risks of these products. The agency has cited counterfeit products, non-FDA-approved ingredients and more than 1,000 adverse event reports tied to compounded semaglutide and tirzepatide.
Bariatric surgery procedures have fallen 46.4% since 2022 as prescriptions for semaglutide and tirzepatide rose to 24.17% of eligible adults by Q3 2025, though 75.8% of eligible patients still receive no treatment.
New research from the University of Missouri-Columbia reveals that targeted cancer therapies, including tyrosine kinase inhibitors, antibody-drug conjugates, and CAR-T cell therapies, cause distinct patterns of gastrointestinal injury that are often underrecognized.
A CNIC study demonstrates that remote ischemic conditioning can protect the heart during anthracycline chemotherapy without compromising antitumor efficacy, while researchers explore additional methods to manage chemotherapy side effects.
Microdosing GLP-1 medications like Ozempic and Wegovy has emerged as a weight-loss trend, but health experts warn there is no scientific data supporting the practice and caution about potential safety risks.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07509905 |
TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOMITING |
COMPLETED | NA |
| NCT07269340 |
Mandala Painting During Chemotherapy |
RECRUITING | NA |
| NCT07208305 |
Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting |
RECRUITING | PHASE3 |
| NCT07179094 |
The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash |
NOT_YET_RECRUITING | NA |
| NCT07169851 |
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer |
RECRUITING | PHASE2 |
| NCT07051616 |
The Effect of Children's Laughter Video on Oncology Patient |
COMPLETED | NA |
| NCT06954935 |
Periorbital Massage for Nausea and Vomiting After Laparoscopic Surgery |
RECRUITING | NA |
| NCT06777758 |
Comparison of Remimazolam and Propofol in Endoscopic Examinations and Treatments |
RECRUITING | PHASE4 |
| NCT06740812 |
Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide |
NOT_YET_RECRUITING | PHASE4 |
| NCT06704698 |
Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery |
RECRUITING | NA |
